Lapointe Gregg Anthony
SEC-identified person · CIK 1331860 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Rigel Pharmaceuticals INC RIGL | Director | filed 2017 - 2026 |
| Catabasis Pharmaceuticals INC CATB | Director | filed 2019 - 2026 |
| Soligenix, INC. SNGX.OB | Director | filed 2009 - 2025 |
| Sciclone Pharmaceuticals INC SCLN | Director | filed 2009 - 2017 |
| Plus Therapeutics, INC. PSTV | Director | filed 2017 - 2017 |
| Torreypines Therapeutics, Inc. TPTX | Director | filed 2015 - 2016 |
| Immunocellular Therapeutics, Ltd. IMUC | Director | filed 2015 - 2016 |
| Questcor Pharmaceuticals INC QSC | Director | filed 2006 - 2010 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.